CX3CR1⁺ CD8⁺ cytotoxic T cells drive tumor killing in esophageal squamous cell carcinoma during neoadjuvant therapy
Immune checkpoint inhibitor (ICI) responses in esophageal squamous cell carcinoma (ESCC) are highly variable, and the immune mechanisms underlying therapeutic sensitivity remain unclear. Here we show, using single-cell RNA, T-cell receptor and whole-exome sequencing of 52 ESCC patients from a phase 3 neoadjuvant trial,...